Condition: Lung Cancer · Sponsor: Creo Medical Limited
This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure. The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.
This description comes directly from the study's public registry record.
Charlie Campion · +44 7939 600137 · Charlie.Campion@creomedical.com
Annie Goulding · +44 1291 606 005 · Annie.Goulding@creomedical.com
Always discuss trial participation with your own doctor first.
| Istituto Europeo di Oncologia (IEO), Via Ripamonti 435 | Milan, Italy | Not Yet Recruiting |
| Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street | London, UK, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06869122